Payment overview · 2025
General Payments
$378,690.70
404 reported records · 20 companies
Healthcare provider profile · identity verified
John Daniel Sheppard, M.D.
Allopathic & Osteopathic Physicians|Ophthalmology · NORFOLK, VA · NPI 1588663702
Verified facts
What the public records show
CMS Open Payments records show John Daniel Sheppard, M.D. received $378,690.70 in general payments during 2025 across 404 reported records.
Mallinckrodt Hospital Products Inc. accounted for 33.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Lumigan, Miebo, Oxervate, Vyzulta, Xiidra.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Lumigan by this doctor in 2024.
Alcon Research LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rhopressa as an associated drug or biological on 32 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Rhopressa by this doctor in 2024.
Alcon Research LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rocklatan as an associated drug or biological on 36 records involving 12 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rocklatan by this doctor in 2024.
Alcon Vision LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rhopressa as an associated drug or biological on 1524 records involving 961 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Rhopressa by this doctor in 2024.
Alcon Vision LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rocklatan as an associated drug or biological on 12237 records involving 5351 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rocklatan by this doctor in 2024.
Alcon Vision LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Simbrinza as an associated drug or biological on 1563 records involving 637 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Simbrinza by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOTEMAX as an associated drug or biological on 10 records involving 10 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Lotemax by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MIEBO as an associated drug or biological on 34133 records involving 12967 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Miebo by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLENSA as an associated drug or biological on 18 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Prolensa by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYZULTA as an associated drug or biological on 10850 records involving 5317 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vyzulta by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIIDRA as an associated drug or biological on 28163 records involving 11019 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Xiidra by this doctor in 2024.
Dompe US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OXERVATE as an associated drug or biological on 19540 records involving 9712 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Oxervate by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $125,299.86 | 33.1% | 104 | 2025 |
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $118,795.60 | 31.4% | 113 | 2025 |
| Dompe US, Inc. | Unresolved — no canonical attribution shown | $56,762.42 | 15.0% | 82 | 2025 |
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $31,520.32 | 8.3% | 21 | 2025 |
| BIOTISSUE HOLDINGS INC. | Unresolved — no canonical attribution shown | $15,628.41 | 4.1% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $11,731.48 | 3.1% | 22 | 2025 |
| Alcon Research LLC | Unresolved — no canonical attribution shown | $7,500.00 | 2.0% | 2 | 2025 |
| Tarsus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4,001.42 | 1.1% | 14 | 2025 |
| Dompe Farmaceutici S.p.A. | Unresolved — no canonical attribution shown | $3,752.42 | 1.0% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $2,665.93 | 0.7% | 3 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $276.38 | 0.1% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $201.69 | 0.1% | 5 | 2025 |
| Glaukos Corporation | Unresolved — no canonical attribution shown | $191.54 | 0.1% | 4 | 2025 |
| Harrow Eye, LLC | Unresolved — no canonical attribution shown | $156.12 | 0.0% | 4 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.32 | 0.0% | 2 | 2025 |
| Thea Pharma Inc. | Unresolved — no canonical attribution shown | $46.71 | 0.0% | 2 | 2025 |
| Rayner Intraocular Lenses Limited | Unresolved — no canonical attribution shown | $37.91 | 0.0% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $28.83 | 0.0% | 1 | 2025 |
| Ocular Therapeutix, Inc. | Unresolved — no canonical attribution shown | $23.11 | 0.0% | 1 | 2025 |
| RxSight Inc | Unresolved — no canonical attribution shown | $17.23 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for serving as faculty or as a speaker for a medical education program | $113,643.75 | 23 |
| Consulting Fee | $108,922.96 | 19 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $108,520.00 | 12 |
| Travel and Lodging | $36,341.78 | 162 |
| Food and Beverage | $8,637.21 | 187 |
| Honoraria | $2,625.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $125,299.86 | 104 | 2025 |
Source payment records
|
|||||
| XIIDRA Normalized: xiidra |
Drug | Bausch & Lomb Americas Inc. | $66,996.17 | 99 | 2025 |
Source payment records
|
|||||
| MIEBO Normalized: miebo |
Drug | Bausch & Lomb Americas Inc. | $66,705.78 | 95 | 2025 |
Source payment records
|
|||||
| OXERVATE Normalized: oxervate |
Drug | Dompe US, Inc. | $56,762.42 | 82 | 2025 |
Source payment records
|
|||||
| TRYPTYR Normalized: tryptyr |
Drug | Alcon Research LLC, Alcon Vision LLC | $32,320.39 | 15 | 2025 |
Source payment records
|
|||||
| PROKERA Normalized: prokera |
Device | BIOTISSUE HOLDINGS INC. | $15,458.94 | 10 | 2025 |
Source payment records
|
|||||
| Crystalens Accommodating IOL (AT-52AO) Normalized: crystalens accommodating iol at 52ao |
Device | Bausch & Lomb Americas Inc. | $8,605.16 | 2 | 2025 |
Source payment records
|
|||||
| STELLARIS ELITE Normalized: stellaris elite |
Device | Bausch & Lomb Americas Inc. | $8,605.16 | 2 | 2025 |
Source payment records
|
|||||
| Trulign IOL Normalized: trulign iol |
Device | Bausch & Lomb Americas Inc. | $8,605.16 | 2 | 2025 |
Source payment records
|
|||||
| enVista MX60 IOL Normalized: envista mx60 iol |
Device | Bausch & Lomb Americas Inc. | $8,605.16 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $2,665.93 | 3 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $276.38 | 6 | 2025 |
Source payment records
|
|||||
| XDEMVY Normalized: xdemvy |
Drug | Tarsus Pharmaceuticals, Inc. | $210.22 | 11 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $201.69 | 5 | 2025 |
Source payment records
|
|||||
| iDoseTR Normalized: idosetr |
Drug | Glaukos Corporation | $166.88 | 2 | 2025 |
Source payment records
|
|||||
| LUMIGAN Normalized: lumigan |
Drug | ABBVIE INC. | $165.86 | 2 | 2025 |
Source payment records
|
|||||
| VEVYE Normalized: vevye |
Drug | Harrow Eye, LLC | $156.12 | 4 | 2025 |
Source payment records
|
|||||
| enVista Envy IOL Normalized: envista envy iol |
Device | Bausch & Lomb Americas Inc. | $150.72 | 2 | 2025 |
Source payment records
|
|||||
| OZURDEX Normalized: ozurdex |
Drug | ABBVIE INC. | $82.31 | 10 | 2025 |
Source payment records
|
|||||
| VYZULTA Normalized: vyzulta |
Drug | Bausch & Lomb Americas Inc. | $56.01 | 1 | 2025 |
Source payment records
|
|||||
| Syfovre Normalized: syfovre |
Drug | Apellis Pharmaceuticals, Inc. | $53.32 | 2 | 2025 |
Source payment records
|
|||||
| IYUZEH Normalized: iyuzeh |
Drug | Thea Pharma Inc. | $46.71 | 2 | 2025 |
Source payment records
|
|||||
| RAYNER CATARACT SET 1 Normalized: rayner cataract set 1 |
Device | Rayner Intraocular Lenses Limited | $37.91 | 1 | 2025 |
Source payment records
|
|||||
| RayOne Aspheric Normalized: rayone aspheric |
Device | Rayner Intraocular Lenses Limited | $37.91 | 1 | 2025 |
Source payment records
|
|||||
| RayOne EMV Normalized: rayone emv |
Device | Rayner Intraocular Lenses Limited | $37.91 | 1 | 2025 |
Source payment records
|
|||||
| RayOne Spheric Normalized: rayone spheric |
Device | Rayner Intraocular Lenses Limited | $37.91 | 1 | 2025 |
Source payment records
|
|||||
| HYDRUS Microstent Normalized: hydrus microstent |
Device | Alcon Vision LLC | $29.03 | 1 | 2025 |
Source payment records
|
|||||
| EYLEA HD Normalized: eylea hd |
Biological | Regeneron Healthcare Solutions, Inc. | $28.83 | 1 | 2025 |
Source payment records
|
|||||
| Centurion Normalized: centurion |
Device | Alcon Vision LLC | $26.96 | 1 | 2025 |
Source payment records
|
|||||
| Clareon Normalized: clareon |
Device | Alcon Vision LLC | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| Xelpros Normalized: xelpros |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| DEXTENZA Normalized: dextenza |
Drug | Ocular Therapeutix, Inc. | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| DURYSTA Normalized: durysta |
Drug | ABBVIE INC. | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| LIGHT ADJUSTABLE LENS (LAL) Normalized: light adjustable lens lal |
Device | RxSight Inc | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT CONTACT LENS Normalized: rxsight contact lens |
Device | RxSight Inc | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR CARTRIDGE Normalized: rxsight injector cartridge |
Device | RxSight Inc | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR HANDPIECE Normalized: rxsight injector handpiece |
Device | RxSight Inc | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT LIGHT DELIVERY DEVICE (LDD) Normalized: rxsight light delivery device ldd |
Device | RxSight Inc | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| Photrexa Viscous and Photrexa Normalized: photrexa viscous and photrexa |
Drug | Glaukos Corporation | $10.10 | 1 | 2025 |
Source payment records
|
|||||
| ScoutPro Osmolarity System Normalized: scoutpro osmolarity system |
Device | Bausch & Lomb Americas Inc. | $5.26 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LUMIGAN lumigan |
2025 | Lumigan | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MIEBO miebo |
2025 | Miebo | 2024 | 49 | exact normalized | Medicare Part D |
| OXERVATE oxervate |
2025 | Oxervate | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYZULTA vyzulta |
2025 | Vyzulta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIIDRA xiidra |
2025 | Xiidra | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Alcon Research LLC Exact reporting entity; no affiliate inference |
2025 | Rhopressa open payments reported associated product |
CMS Open Payments — General Payments 32 supporting records · 8 recipient NPIs · example record 1207325611 |
Rhopressa · 2024 Exact normalized brand match · 1 Part D row |
74 | 31 |
| Alcon Research LLC Exact reporting entity; no affiliate inference |
2025 | Rocklatan open payments reported associated product |
CMS Open Payments — General Payments 36 supporting records · 12 recipient NPIs · example record 1207325557 |
Rocklatan · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Alcon Vision LLC Exact reporting entity; no affiliate inference |
2025 | Rhopressa open payments reported associated product |
CMS Open Payments — General Payments 1524 supporting records · 961 recipient NPIs · example record 1207357314 |
Rhopressa · 2024 Exact normalized brand match · 1 Part D row |
74 | 31 |
| Alcon Vision LLC Exact reporting entity; no affiliate inference |
2025 | Rocklatan open payments reported associated product |
CMS Open Payments — General Payments 12237 supporting records · 5351 recipient NPIs · example record 1207357016 |
Rocklatan · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Alcon Vision LLC Exact reporting entity; no affiliate inference |
2025 | Simbrinza open payments reported associated product |
CMS Open Payments — General Payments 1563 supporting records · 637 recipient NPIs · example record 1207357100 |
Simbrinza · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | LOTEMAX open payments reported associated product |
CMS Open Payments — General Payments 10 supporting records · 10 recipient NPIs · example record 1254762767 |
Lotemax · 2024 Exact normalized brand match · 1 Part D row |
45 | 18 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | MIEBO open payments reported associated product |
CMS Open Payments — General Payments 34133 supporting records · 12967 recipient NPIs · example record 1254730224 |
Miebo · 2024 Exact normalized brand match · 1 Part D row |
49 | 19 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | PROLENSA open payments reported associated product |
CMS Open Payments — General Payments 18 supporting records · 13 recipient NPIs · example record 1254766966 |
Prolensa · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | VYZULTA open payments reported associated product |
CMS Open Payments — General Payments 10850 supporting records · 5317 recipient NPIs · example record 1254730226 |
Vyzulta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | XIIDRA open payments reported associated product |
CMS Open Payments — General Payments 28163 supporting records · 11019 recipient NPIs · example record 1254730224 |
Xiidra · 2024 Exact normalized brand match · 1 Part D row |
62 | 22 |
| Dompe US, Inc. Exact reporting entity; no affiliate inference |
2025 | OXERVATE open payments reported associated product |
CMS Open Payments — General Payments 19540 supporting records · 9712 recipient NPIs · example record 1248849978 |
Oxervate · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisolone Acetate | Prednisolone Acetate | 567 | 251 |
| Moxifloxacin | Moxifloxacin Hcl | 327 | 116 |
| Brimonidine Tartrate | Brimonidine Tartrate | 320 | 123 |
| Restasis | Cyclosporine | 287 | 132 |
| Loteprednol Etabonate | Loteprednol Etabonate | 252 | 89 |
| Latanoprost | Latanoprost | 201 | 79 |
| Difluprednate | Difluprednate | 179 | 69 |
| Valacyclovir | Valacyclovir Hcl | 174 | 45 |
| Cyclosporine | Cyclosporine | 155 | 64 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 135 | 91 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 129 | 38 |
| Diclofenac Sodium | Diclofenac Sodium | 126 | 61 |
| Dorzolamide Hcl | Dorzolamide Hcl | 126 | 40 |
| Memantine Hcl Er | Memantine Hcl | 111 | 34 |
| Alphagan P | Brimonidine Tartrate | 94 | 22 |
| Timolol Maleate | Timolol Maleate | 88 | 35 |
| Montelukast Sodium | Montelukast Sodium | 76 | 23 |
| Rhopressa | Netarsudil Mesylate | 74 | 31 |
| Tobramycin | Tobramycin | 74 | 48 |
| Pilocarpine Hcl | Pilocarpine Hcl | 63 | 21 |
| Xiidra | Lifitegrast | 62 | 22 |
| Combigan | Brimonidine Tartrate/Timolol | 55 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 21 |
| Memantine Hcl | Memantine Hcl | 54 | 11 |
| Miebo | Perfluorohexyloctane/Pf | 49 | 19 |
| Simbrinza | Brinzolamide/Brimonidine Tart | 46 | suppressed |
| Lotemax | Loteprednol Etabonate | 45 | 18 |
| Atropine Sulfate | Atropine Sulfate | 40 | 22 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 40 | 18 |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 38 | 20 |
| Acyclovir | Acyclovir | 36 | suppressed |
| Fluorometholone | Fluorometholone | 36 | 14 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 34 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 30 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 30 | suppressed |
| Travoprost | Travoprost | 28 | suppressed |
| Lumigan | Bimatoprost | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 16 |
| Gentamicin Sulfate | Gentamicin Sulfate | 26 | 14 |
| Levobunolol Hcl | Levobunolol Hcl | 26 | suppressed |
| Prolensa | Bromfenac Sodium | 25 | suppressed |
| Humira(Cf) Pen | Adalimumab | 22 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Oxervate | Cenegermin-Bkbj | 20 | suppressed |
| Tyrvaya | Varenicline Tartrate | 19 | suppressed |
| Acetazolamide | Acetazolamide | 18 | suppressed |
| Durezol | Difluprednate | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | 11 |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 14 | suppressed |
| Vyzulta | Latanoprostene Bunod | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $378,690.70 · 404 records | Mallinckrodt Hospital Products Inc. | ACTHAR, Centurion, Cequa, Clareon, Crystalens Accommodating IOL (AT-52AO), DEXTENZA, DURYSTA, EYLEA HD, HYDRUS Microstent, IYUZEH, LIGHT ADJUSTABLE LENS (LAL), LUMIGAN, MIEBO, OXERVATE, OZURDEX, PROKERA, PURIFIED CORTROPHIN GEL, Photrexa Viscous and Photrexa, RAYNER CATARACT SET 1, RXSIGHT CONTACT LENS, RXSIGHT INJECTOR CARTRIDGE, RXSIGHT INJECTOR HANDPIECE, RXSIGHT LIGHT DELIVERY DEVICE (LDD), RayOne Aspheric, RayOne EMV, RayOne Spheric, STELLARIS ELITE, ScoutPro Osmolarity System, Syfovre, TEPEZZA, TRYPTYR, Trulign IOL, VEVYE, VYZULTA, XDEMVY, XIIDRA, Xelpros, enVista Envy IOL, enVista MX60 IOL, iDoseTR | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Lumigan play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error